ARCHIVES

ACS Defends Dialogue, Calls Story “Misleading”.

This article is from The Cancer Letter archive.

Vol. 26 No. 38 | October 20, 2000

Download PDF Visit The Full Archive

Related Articles

Cancer Advocacy: March On Washington Scheduled For September 1998

October 31, 1997

Two Phase II Studies of Ibrutinib Deliver High Response Rates

December 27, 2013

Obey Explains Cuts In Control, Construction Funds; House Passes HEW Appropriations Bill

July 6, 1979

Cobimetinib-Zelboraf Therapy Increases OS In BRAF V600 Mutation-Positive Disease

October 31, 2014

Harvard’s Harvey Fineberg Is Elected IOM President.

November 16, 2001

NCI-Approved Clinical Trials

August 31, 2001